EFFICACY AND SAFETY OF FERRIC CARBOXYMALTOSE IN MODERATE TO SEVERE IRON DEFICIENCY ANEMIA DURING PREGNANCY AT A TERTIARY CARE HOSPITAL

Abstract

Iron deficiency anemia (IDA) is one of the most common nutritional disorders during pregnancy and is associated with adverse maternal and fetal outcomes. Ferric carboxymaltose (FCM) is a newer intravenous iron formulation that allows rapid correction of iron deficiency with a favorable safety profile. To evaluate the efficacy and safety of ferric carboxymaltose in pregnant women with moderate to severe iron deficiency anemia at a tertiary care hospital. A prospective observational study was conducted among pregnant women diagnosed with moderate to severe iron deficiency anemia attending a tertiary care hospital. Eligible participants received intravenous ferric carboxymaltose according to standard treatment protocols. Hemoglobin and serum ferritin levels were assessed before treatment and during follow-up. The primary outcome was improvement in hemoglobin concentration, while secondary outcomes included changes in serum ferritin levels and the occurrence of adverse drug reactions. Administration of ferric carboxymaltose resulted in a significant increase in mean hemoglobin and serum ferritin levels following treatment. Most participants achieved satisfactory hematological improvement within the follow-up period. The treatment was generally well tolerated, with only mild and transient adverse effects reported. No serious maternal or fetal complications related to ferric carboxymaltose were observed. Ferric carboxymaltose is an effective and safe treatment option for moderate to severe iron deficiency anemia during pregnancy. It provides rapid replenishment of iron stores, improves hemoglobin levels, and demonstrates a favorable safety profile, making it a valuable therapeutic option in routine obstetric practice.